Cargando…

The Expression Pattern and Regulatory Mechanism of the G0/G1 Switch Gene 2 (G0S2) in the Pathogenesis and Treatment of AChR Myasthenia Gravis (MG)

This study is aimed at exploring the expression pattern and methylation level of G0S2 in the peripheral blood mononuclear cells (PBMCs) of myasthenia gravis (MG) patients with positive acetylcholine receptor (AChR) autoantibodies and revealing the relationship between the G0S2 methylation pattern an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Liqun, Li, Zhibin, Li, Yi, Luo, Zhaohui, Luo, Yuebei, Xiao, Bo, Yang, Huan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545457/ https://www.ncbi.nlm.nih.gov/pubmed/33061827 http://dx.doi.org/10.1155/2020/4286047

Ejemplares similares

Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs
por: Cetin, Hakan, et al.
Publicado: (2020)

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
por: Zhao, Rui, et al.
Publicado: (2021)

Diffuse Gonococcal Infection (DGI) in a Patient with Treatment-Refractory Acetylcholine Receptor Antibody-Positive (AChR+) Generalized Myasthenia Gravis (gMG) Treated with Eculizumab
por: Katyal, Nakul, et al.
Publicado: (2021)

A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis
por: Cai, Yu, et al.
Publicado: (2021)

SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody
por: Huda, Saif, et al.
Publicado: (2019)

Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
por: Kordas, Gregory, et al.
Publicado: (2014)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK
por: Yilmaz, Vuslat, et al.
Publicado: (2015)

Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis
por: Lee, Jae‐Yun, et al.
Publicado: (2016)

Plasma Myokine Profiles in Patients With AChR- and MuSK-Ab-Positive Myasthenia Gravis
por: Seok, Jo Woon, et al.
Publicado: (2023)

The Clinical Outcome in AChR-Positive Generalized Myasthenia Gravis: A Retrospective Observational Study
por: Ojha, Pawan T., et al.
Publicado: (2023)

Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis
por: Bastakoti, Sanjiv, et al.
Publicado: (2021)

Correction: Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
Publicado: (2015)

Correction: Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients
Publicado: (2015)

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient
por: Saxena, Abhishek, et al.
Publicado: (2017)

Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort
por: Lupica, Antonino, et al.
Publicado: (2022)

Oral Microbiota Profile in a Group of Anti-AChR Antibody–Positive Myasthenia Gravis Patients
por: Huang, Chao, et al.
Publicado: (2022)

MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters
por: Koneczny, Inga, et al.
Publicado: (2013)

Autoantibody of NRIP, a novel AChR‐interacting protein, plays a detrimental role in myasthenia gravis
por: Tsai, Li‐Kai, et al.
Publicado: (2021)

Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis
por: Spagni, Gregorio, et al.
Publicado: (2022)

Clinical Outcomes in AchR Antibody-Positive Myasthenia Gravis: Where Does Rituximab Stand in the Current Times?
por: Dhamne, Megha Chetan
Publicado: (2023)

The Association of PTPN22 R620W Polymorphism Is Stronger with Late-Onset AChR-Myasthenia Gravis in Turkey
por: Kaya, Gizem A., et al.
Publicado: (2014)

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis
por: Huan, Xiao, et al.
Publicado: (2022)

Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody
por: Chen, Yuping, et al.
Publicado: (2022)

Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes
por: Luo, ZhaoHui, et al.
Publicado: (2015)

FoxP3(−) Tr1 Cell in Generalized Myasthenia Gravis and Its Relationship With the Anti-AChR Antibody and Immunomodulatory Cytokines
por: Meng, Huanyu, et al.
Publicado: (2021)

Juvenile Generalized Myasthenia Gravis With AChR and MuSK Antibody Double Positivity: A Case Report With a Review of the Literature
por: Ge, XiuShan, et al.
Publicado: (2022)

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review
por: Waheed, Waqar, et al.
Publicado: (2022)

Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
por: Lekova, Eleonora, et al.
Publicado: (2022)

IgG1-3 MuSK Antibodies Inhibit AChR Cluster Formation, Restored by SHP2 Inhibitor, Despite Normal MuSK, DOK7, or AChR Subunit Phosphorylation
por: Cao, Michelangelo, et al.
Publicado: (2023)

Tas2R activation relaxes airway smooth muscle by release of Gα(t) targeting on AChR signaling
por: Zhou, Yu-Wei, et al.
Publicado: (2022)

Slow‐channel myasthenia due to novel mutation in M2 domain of AChR delta subunit
por: Shen, Xin‐Ming, et al.
Publicado: (2019)

Myasthenia Gravis With Thymoma, Manifesting as AChR-Ab-Positive, Distinct Bulbar Palsy Accompanied by Dysgeusia: A Case Series and Review of Literature
por: Zhu, Kai, et al.
Publicado: (2018)

A Patient with Fulminant Myasthenia Gravis Is Seropositive for Both AChR and LRP4 Antibodies, Complicated by Autoimmune Polyglandular Syndrome Type 3
por: Inoue, Hiroyasu, et al.
Publicado: (2020)

Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neuroimmunology Clinic in a Developing Country
por: Mathew, Thomas, et al.
Publicado: (2021)

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]
Publicado: (2022)

ACHR-Positive Generalized Myasthenia Gravis: The Old is Gold and the New Is for us to Explore
por: Hiew, Fu Liong
Publicado: (2023)

Association of HLA-DQB1∗05:02 and DRB1∗16 Alleles with Late-Onset, Nonthymomatous, AChR-Ab-Positive Myasthenia Gravis
por: Testi, Manuela, et al.
Publicado: (2012)

Metformin Triggers Apoptosis and Induction of the G0/G1 Switch 2 Gene in Macrophages
por: Hu, Xuming, et al.
Publicado: (2021)

Regulation of G0/G1 Switch Gene 2 (G0S2) Protein Ubiquitination and Stability by Triglyceride Accumulation and ATGL Interaction
por: Heckmann, Bradlee L., et al.
Publicado: (2016)

Impaired gating of γ‐ and ε‐AChR respectively causes Escobar syndrome and fast‐channel myasthenia
por: Shen, Xin‐Ming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_siek8ek6hbll0q2o259ssd439a